ANCA VASCULITIS DRUG MARKET ANALYSIS

ANCA Vasculitis is a type of autoimmune disease that causes vasculitis, swelling or inflammation of blood vessels. ANCA stands for Anti-Neutrophilic Cytoplasmic Autoantibody. ANCA vasculitis is an autoimmune disease affecting small blood vessels in the body. Neutrophils are a particular subset of white blood cells that are the target of ANCAs, autoantibodies causing the disease. They target the cytoplasm of neutrophils (the inside of the cell). Neutrophils attack the body's small blood vessels when ANCAs (the autoantibodies) adhere to them. This is how vasculitis, or blood vessel inflammation, develops in this condition.

Global ANCA vasculitis drug market is estimated to be valued at US$ 463.82 million in 2022 and is expected to exhibit a CAGR of 5.5% during the forecast period (2022-2030).

Figure 1.Global ANCA Vasculitis Drug Market Share (%), by Type, 2022

To learn more about this report, request sample copy

Increasing approvals for ANCA vasculitis drugs by the regulatory bodies is expected to drive growth of the ANCA vasculitis drug market

Key players in market are focused on receiving approvals from the regulatory bodies for drugs used to treat ANCA vasculitis, which is expected to drive the market growth over the forecast period. For instance, in October 2021, ChemoCentryx, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA vasculitis), in combination with standard therapy.

Figure 2.Global ANCA Vasculitis Drug Market Share (%), by Distribution Channel, 2022

To learn more about this report, request sample copy

Increasing research and development activities by key players in market to develop ANCA vasculitis drugs are expected to drive the market growth during the forecast period.

Key players in market are focused on carrying out research and development activities for the development of ANCA vasculitis drugs, which is expected to drive the market growth over the forecast period. For instance, in November 2021, InflaRx N.V., a clinical-stage biopharmaceutical company, announced positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV). The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to standard of care, while significantly reducing the need for glucocorticoid (GC) treatment in this life-threatening indication

Global ANCA Vasculitis Drug Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another

The COVID-19 pandemic had a negative economic impact on the global ANCA vasculitis market, owing to the direct impact of the pandemic on not going to hospitals and undertaking laboratory and other tests. Higher density of immunosuppression (including prednisone use of more than 10 mg a day) was associated with a greater likelihood of avoiding tests or visits. For instance, according to an article published by the National Center for Biotechnology Information, in October 2021, an alarming number of patients (10.5%) stopped their immunosuppression, without consultation with their managing physician. Thus, the COVID-19 pandemic had a negative impact on the global ANCA vasculitis market.

Global ANCA Vasculitis Drug Market: Restraint

The major factors that hinder growth of the global ANCA vasculitis drug market include side effects associated with glucocorticoid use such as glucocorticoid toxicity. Higher doses of steroids in ANCA-associated vasculitis (AAV) lead to worse glucocorticoid-related toxicity. Although glucocorticoids remain the main adjunctive immunosuppression of AAV treatment, the narrow therapeutic window supports the need for glucocorticoids-sparing treatments, thus acting as a restraint for the market growth.

Key Players

Major players operating in the global ANCA vasculitis drug market include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca.